JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

Search

IQVIA Holdings Inc

Abrir

SetorSaúde

239 -0.96

Visão Geral

Variação de preço das ações

24h

Atual

Mín

236.29

Máximo

240.89

Indicadores-chave

By Trading Economics

Rendimento

66M

332M

Vendas

83M

4.1B

P/E

Médio do Setor

32.889

90.422

Margem de lucro

8.098

Funcionários

91,000

EBITDA

102M

883M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+8.12% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.3B

41B

Abertura anterior

239.96

Fecho anterior

239

Sentimento de Notícias

By Acuity

50%

50%

148 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

IQVIA Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jan. de 2026, 23:07 UTC

Ganhos

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 de jan. de 2026, 21:27 UTC

Ganhos

Texas Instruments 4Q Sales Rise, Profit Falls

27 de jan. de 2026, 23:55 UTC

Conversa de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 de jan. de 2026, 23:39 UTC

Conversa de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation Posts Net Loss for Second Consecutive Year

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 de jan. de 2026, 23:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 de jan. de 2026, 22:17 UTC

Conversa de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 de jan. de 2026, 22:06 UTC

Ganhos

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 de jan. de 2026, 21:51 UTC

Ganhos

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

27 de jan. de 2026, 21:43 UTC

Ganhos

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 de jan. de 2026, 21:41 UTC

Ganhos

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 de jan. de 2026, 21:38 UTC

Ganhos

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: Modest Profit From F&I International in 2025

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 de jan. de 2026, 21:30 UTC

Ganhos

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 de jan. de 2026, 21:28 UTC

Ganhos

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Comparação entre Pares

Variação de preço

IQVIA Holdings Inc Previsão

Preço-alvo

By TipRanks

8.12% parte superior

Previsão para 12 meses

Média 260.62 USD  8.12%

Máximo 290 USD

Mínimo 230 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para IQVIA Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

11

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

150.68 / 153.45Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

148 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat